Japan PMDA's investigation results for five products

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1686卷 / 1期

关键词：

D O I：

10.1007/s40278-018-41069-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：5 / 5

相关论文

共 50 条

[31] Japan's PMDA releases updated risk report for telaprevir
Reactions Weekly, 2012, 1408 (1) : 2 - 2
[32] Package insert revisions required: Japan's PMDA findings
Reactions Weekly, 2016, 1615 (1) : 4 - 4
[33] Japan's PMDA revises package inserts for memantine, bevacizumab
Reactions Weekly, 2020, 1810 (1) : 2 - 2
[34] Japan's MHLW/PMDA recommends package insert revisions
Reactions Weekly, 2018, 1732 (1) : 1 - 1
[35] Japan's PMDA issues precautions update for aminolevulinic acid hydrochloride
Reactions Weekly, 2022, 1891 (1) : 1 - 1
[36] Japan's PMDA set to launch new medical information database
Reactions Weekly, 2018, 1695 (1) : 2 - 2
[37] New ADRs for two drugs in PMDA's September results
Reactions Weekly, 2017, 1670 (1) : 5 - 5
[38] Japan's PMDA warns of serious AEs with pivoxil use in kids
Reactions Weekly, 2012, 1407 (1) : 2 - 2
[39] Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–2022
Ryosuke Kuribayashi
Ayuki Nakano
Aya Hariu
Yasuhiro Kishioka
Futaba Honda
BioDrugs, 2023, 37 : 443 - 451
[40] Japan PMDA's Relief System for ADRs: 5-year analysis
Reactions Weekly, 2018, 1727 (1) : 2 - 2

← 1 2 3 4 5 →